

## Definition (IWG 2009)

Isolated thrombocytopenia **platelets < 100 × 10<sup>9</sup>/L** in the absence of any identifiable underlying cause. Diagnosis of **exclusion** — no single test confirms ITP. Prior threshold was <150; updated by IWG 2009.

## Classification by duration (IWG 2009)

Newly Diagnosed	Persistent	Chronic
< 3 months	3 – 12 months	> 12 months
From diagnosis	Not in remission	>12 m from diagnosis

## ■ WHEN TO TREAT vs OBSERVE (ASH 2019)

Clinical situation	Approach	Action / note
Plt ≥ 30 × 10 <sup>9</sup> /L + no bleeding	<b>OBSERVE</b>	Repeat FBC 1–2 weeks; patient education on bleeding signs
Plt < 30 × 10 <sup>9</sup> /L + asymptomatic / minor bruising	<b>Individualise</b>	Consider patient lifestyle, age, comorbidities; steroids if treating
Any count + significant mucosal bleeding	<b>TREAT</b>	Prednisolone ± IVIG; add tranexamic acid for mucosal bleeding
Any count + upcoming surgery / invasive procedure	<b>TREAT pre-procedure</b>	Target plt ≥ 50 (minor), ≥ 80–100 (major/neuraxial); IVIG for speed
Any count + severe/life-threatening bleeding	<b>EMERGENCY — see below</b>	IV methylprednisolone + IVIG + platelet transfusion
Chronic ITP, plt 20–50, no bleeding	<b>Often OBSERVE</b>	Avoid prolonged steroids for count maintenance alone

## A FIRST-LINE TREATMENT (ASH 2019)

Agent	Approval	Key data
<b>A — Prednisolone</b> Standard first-line 1 mg/kg/day (max 80 mg/day) × 2–4 weeks, then taper 70–80% initial response; <30% durable remission <b>Do not continue beyond 6 weeks (ASH 2019)</b>		
<b>B — Dexamethasone</b> 40 mg/day × 4 days; up to 3 cycles (14–28-day intervals) Similar long-term remission to prednisolone at 6–12 months		
<b>C — IVIG</b> 1 g/kg IV; repeat after 24 h if needed (max 2 g/kg total) Plt rises within 24–48 h; effect lasts 2–4 weeks		
<b>D — H. pylori eradication</b> Test all newly diagnosed. Eradication may improve plt count		

## B SECOND-LINE OPTIONS

<b>Romiplostim (SC weekly)</b>	<b>NICE TA221</b>	79–88% response (NICE TA221)
<b>Avatrombopag (oral OD)</b>	<b>NICE TA853</b>	Approved Dec 2022; oral TPO-RA (NICE TA853)
<b>Rituximab 375 mg/m<sup>2</sup> × 4</b>	<b>Off-label</b>	~60% initial; ~20% 5-yr remission [1,2]
<b>Splenectomy</b>	<b>Surgical</b>	60–70% LT response; defer ≥12 m; pre-op vaccines essential [1]

*TPO-RAs do not induce remission — relapse on discontinuation is common. Bone marrow biopsy required before splenectomy.*

## ■ EMERGENCY MANAGEMENT — SEVERE / LIFE-THREATENING BLEEDING

1. Haematology on-call — do not manage in isolation	2. IV methylprednisolone 1 g/day × 3 days (or high-dose IV dexamethasone)	3. IVIG 1 g/kg — repeat after 24 h if needed
4. Platelet transfusion — at least 2 adult doses; combine with IVIG	5. Tranexamic acid 1 g TDS for mucosal bleeding	6. ICH: neurosurgery + ICU involvement; consider emergency splenectomy

## ■ PLATELET TRANSFUSION — KEY PRINCIPLE

**NOT routine in ITP.** Transfused platelets are destroyed by the same immune mechanism. Indication: active severe/life-threatening bleeding or urgent surgery — not a low platelet count alone. Give ≥ 2 adult doses; combine with IVIG to prolong survival.

## ✗ KEY PITFALLS — AVOID THESE

- Blood film before any treatment — exclude pseudothrombocytopenia & TTP
- Exclude TTP before starting steroids (check film for schistocytes)
- Do not treat plt ≥ 30 + no bleeding — ASH 2019: observe
- Do not prolong steroids beyond 6 weeks — plan second-line instead
- Do not transfuse platelets prophylactically — only for active bleeding
- Check HIV + HCV in all patients — treatable causes of thrombocytopenia
- Test all for H. pylori at diagnosis